Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells

Epigenetics

Volumn 6, Issue 10, 2011, Pages 1228-1235

  Pérez Perarnau, Alba ^a   Coll Mulet, Llorenç ^a   Rubio Patiño, Camila ^a   Iglesias Serret, Daniel ^a   Cosialls, Ana M ^a   González Gironès, Diana M ^a   de Frias, Mercè ^a   de Sevilla, Alberto Fernández ^b   de la Banda, Esmeralda ^c   Pons, Gabriel ^a   Gil, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b IDIBELL Institut Català d'Oncologia   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Apoptosis; CLL; HDAC; Kendines; MLPA; SAHA; TP53

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; BCL2 RELATED PROTEIN A1; BIM PROTEIN; CASPASE; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KENDINE 92; MESSENGER RNA; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BNIP3; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATOR GENE; SIGNAL TRANSDUCTION;

EID: 80053449103     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.10.17200     Document Type: Article

References (35)

1. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84.
2. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51.
3. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19-25.
4. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459-68.
5. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-9.
6. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010; 19:1049-66.
7. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280:125-33.
8. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008; 371:1017-29.
9. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11:193-206.
10. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia 2005; 19:2195-202.
11. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92:3804-16.
12. Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, et al. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004; 18:1207-14.
13. Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, et al. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 2007; 35:1527-37.
14. Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by bim and noxa. Leukemia 2007; 21:1773-82.
15. Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res 2008; 14:549-58.
16. 1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity. Oncogene 2009; 28:1477-84.
17. Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010; 95:1136-43.
18. El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH, et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010; 9:1349-60.
19. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5:10941.
20. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11:77-84.
21. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11:71-6.
22. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37:299-310.
23. Inoue S, Walewska R, Dyer MJ, Cohen GM. Downregulation of mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 2008; 22:819-25.
24. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009; 23:2281-9.
25. Otaegui D, Rodriguez-Gascon A, Zubia A, Cossio FP, Pedraz JL. Pharmacokinetics and tissue distribution of kendine 91, a novel histone deacetylase inhibitor, in mice. Cancer Chemother Pharmacol 2009; 64:153-9.
26. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153:657-68.
27. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107:4109-14.
28. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144:41-52.
29. Bokelmann I, Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 2008; 14:20-7.
30. Subramanian C, Opipari AW Jr, Bian X, Castle VP, Kwok RP Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102:4842-7.
31. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suber-oylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111:1060-6.
32. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105:959-67.
33. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009; 147:507-14.
34. Otaegui D, Rodriguez-Gascon A, Zubia A, Cossio FP, Pedraz JL. Development and validation of a liquid chromatography-tandem mass spectrometry for the determination of kendine 91, a novel histone deacetylase inhibitor, in mice plasma and tissues: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 870:109-16.
35. Eldering E, Spek CA, Aberson HL, Grummels A, Derks IA, de Vos AF, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003; 31:153.